0001169245-20-000109.txt : 20201204
0001169245-20-000109.hdr.sgml : 20201204
20201204155337
ACCESSION NUMBER: 0001169245-20-000109
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201203
FILED AS OF DATE: 20201204
DATE AS OF CHANGE: 20201204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HARRIGAN EDMUND
CENTRAL INDEX KEY: 0001177917
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 201369851
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4
1
wf-form4_160711520255981.xml
FORM 4
X0306
4
2020-12-03
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001177917
HARRIGAN EDMUND
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
1
0
0
0
Common Stock
2020-12-03
4
P
0
6000
4.12
A
6000
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.11 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
/s/ John Sharp, Attorney-in-fact
2020-12-04